Summary ** ***** ******* ********
** * ******** ****** ** *** patent ******, *** ** *** 17 ****** **** ** Arecont's ******** ****** **** deemed ** ** *********** unpatentable. **** ******** ** based ** ****** ** prior *** *** ***** evidence ******** ** **** in ***** *********:

***** ** **** ********, the ****** ********* ***** ** to * *****, *** ultimately * ***** ******** that **** ******, ** invalidate, *******'* ****** ******.
Axis ************ *********
**** ****** *******'* ****** is ******* ******* **** ***** **/******* 103, ***** ****** *** approach ** "*******" ***** on ***** ***/******** *******. **** submitted ** ******** ******* with ******** ** **** prior ***, ******* ******** challenges ** **** ** the ** ****** ** patentability ******* **** ** its ******* ****** ***********. Arecont ***** ******** *****-****** ****** ** April ****. **** ** ****' claims ** ***** *** include:
- ** ****** *,***,*** - Dating **** ** ****
- ** ****** *,***,*** - 1998
- ** ****** *,***,*** - 2006
- ** ****** *,***,*** - 2009
- ** ****** **,***,***,*** - 2010
******* **** *** ****** *** "obvious" ** * "******* artisan", ** ****** *********** in ****** ******** ** indicate **** *** ****** concept **** ***** **** been ******* ** ** any ****** ******* ** the *** ** ***** such ******* (**** **** companies ********* ***** *** use "*********" ********* *** such ********). **** ***** it ************, ******* *** design ** ********* *** unique ****** ** ******* a ****** *** ***** have **** ********* ** any ********* ********.

Next *****
* ********** ***** ******** * ****** ** 7 *** ***** *** deadlines *** **** **** and ******* ** ******* the ****** *******, *** to ****** ********** ********* or ********** ** ***** claims. ***** *** ***** and ***** ****** ******** ************* for ******* ** ****** their ******, *** *** Axis ** ******* ** any ********** ****** ** information ******** ** *******.
*** ** *** *** dates *** ** ********** interest:
*** **** *: ******** 27, **** - ******* has ***** **** **** to ******* ***** ******** to *** ******** ** file *** ******* ** amend *** ******. ** far, **** **** *** provided *** ********** ********, though **** **** ******* weeks **** ** ** so. *******'* ********, ** lack ** ***, **** likely *** *** ****, and ************, *** *** rest ** *** *******. Not ****** * ******** is * ****-********* **** the ****** ** *** valid.
*** **** *: ****** 21, **** - ***** oral ********* **** ** front ** ****** ****** panel, **** * ******** being ****** ** ** shortly ***** **** ****.
Arecont ********
******* ******* *** ********* statement ** ******** ** this **** ********** ** trial:
*********, ** *** ******* to ******* *** ******* positioning ********* *** *******. However, * **** ** comment ********* *** ******** litigation.
Impact ** ****** ***********
****** ***** ****** *********** could ********** ****** *** overall ********* ** *** company, ************ ** ******* intends ** **** * new ***** ***** ***** ******** ********* **** **** through. ****, **** ***** eliminate *** *********** ** Arecont ******* ****** ******* revenue ******** ** **** Avigilon *** **** ***** over *** **** *** years.
*******, * **** ** the ****** ** ******** ** put *** ******* ** significant ********** **** ** competitors ******* *********** ** their *****-****** ****** *****. Several ***** ********* **** already ******* *****-****** ******* (e.g.********, ****,*****, ******, *********). *******, *******' *** quality ******** *** **** reputation ******** ** **** it ******* *** **** larger ****** ** *** multi-imager *****.
***** *** ***** ****** invalidation ******** ***** **** Arecont's ***** ****-*** / exit ********, *** ****** in **** ***** ******* means **** *** ****** impact ****** ** *****.
Comments (0)